Efficacy of Merck/Ridgeback’s molnupiravir shows an alarming fall-off, just as a US regulatory panel review beckons.
A front-line trial yields a positive result two years after the drug got a US complete response letter.
Followers of novel immuno-oncology mechanisms will note Astrazeneca as a new player in Tigit and Tim3.
An adagrasib/Keytruda combo in front-line lung cancer looks promising, but patient numbers are small and Amgen looms large.
But whether data on the novel anaemia pill are clean enough to dispel wider FDA toxicity concerns is hard to call.
But investors will need more convincing; and others are more advanced, with Arrowhead and Inhibrx ones to watch.
Cenerimod flunks a mid-stage lupus study, so Idorsia moves to go straight into phase 3. What can possibly go wrong?
While Lilly has thrown in the tau towel with zagotenemab, Cortexyme still sees reasons to press on with atuzaginstat.
Lilly's remarkable decision to run a head-to-head trial of donanemab versus Aduhelm spells another big readout for the amyloid targeting space.